We are Redefining Drug Discovery for Disordered Proteins

Stuart has over 25 years experience in biomedical research conducted across a range of therapeutic areas and in both academic and industrial contexts. His previous role was as CEO of Pathios Therapeutics, a company targeting the proton sensing GPCR, GPR65, with small molecule inhibitors for applications in immuno-oncology and immunology. In this role he led the company from initial hit finding through to clinical development in oncology, securing investment from Bristol Myers Squibb along the way as part of a Series B capital raise. He is also co-founder of ThirtyFiveBio, a company developing genetically-informed precision treatments for digestive system disorders. Prior to Pathios, Stuart was Senior Director at Vertex Pharmaceuticals where he led multiple drug discovery projects in the specialty disease space. He also spent several years at Eli Lilly working across the neuroscience portfolio. Initially trained in mathematics, engineering and neurobiology, Stuart has published extensively on the cellular and network mechanisms of physiological and pathological brain rhythms, making key contributions to the understanding slow sleep waves and the enigmatic human alpha rhythm. He holds a PhD in Neuroscience from Cardiff Unversity as well as an MSc in Electronic Engineering and a BSc in Pure and Applied Mathematics.

Prior to joining Nuage, Olivier was the Head of Medicinal Chemistry group at Idorsia where he led the Chemistry Oncology that delivered several pre-clinical candidates, including an EP2/EP4 dual antagonist that entered clinical development. Prior to this, in his work as project leader at Actelion, Olivier participated in the discovery of 4 compounds which entered clinical development, including the first FPR2 modulator that brought the concept of the resolution of inflammation into the clinic. Olivier holds a PhD from the University of Fribourg.

Julia joined Nuage Tx in 2025 as the Operations & Communications Manager. Before joining Nuage, Julia project managed the initial setup and operations of the Barcelona Collaboratorium for Modelling and Predictive Biology, a joint initiative between EMBL Barcelona and the Centre de Regulació Genòmica (CRG). Prior to that, she was responsible for delivering multimillion-pound capital projects funded by UKRI at EMBL-EBI. Before, she also coordinated the delivery of the IT transformation at Churchill College (University of Cambridge). Julia holds a master’s degree in Political Communication from Cardiff University and a bachelor’s degree in Political Science and Public Administration from Pompeu Fabra University (UPF).

Stuart has over 25 years experience in biomedical research conducted across a range of therapeutic areas and in both academic and industrial contexts. His previous role was as CEO of Pathios Therapeutics, a company targeting the proton sensing GPCR, GPR65, with small molecule inhibitors for applications in immuno-oncology and immunology. In this role he led the company from initial hit finding through to clinical development in oncology, securing investment from Bristol Myers Squibb along the way as part of a Series B capital raise. He is also co-founder of ThirtyFiveBio, a company developing genetically-informed precision treatments for digestive system disorders. Prior to Pathios, Stuart was Senior Director at Vertex Pharmaceuticals where he led multiple drug discovery projects in the specialty disease space. He also spent several years at Eli Lilly working across the neuroscience portfolio. Initially trained in mathematics, engineering and neurobiology, Stuart has published extensively on the cellular and network mechanisms of physiological and pathological brain rhythms, making key contributions to the understanding slow sleep waves and the enigmatic human alpha rhythm. He holds a PhD in Neuroscience from Cardiff University as well as an MSc in Electronic Engineering and a BSc in Pure and Applied Mathematics.